GSK China Problems Lead Other MNCs To Risk Consultants For Advice
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline's alleged corruption problems in China have led several multinational drug makers to seek the advice from consulting companies familiar with the risks associated with doing business in the country.